356P Efficacy and safety analysis of anlotinib and durvalumab plus chemotherapy in first-line therapy extensive-stage small cell lung cancer (SCLC)

IMpower133 and CASPIAN showed that the combination of PD-L1 monoclonal antibody and EC regimen chemotherapy as first-line treatment of small cell lung cancer have a median PFS (progession-free survival) of about 5 months, which is comparable to that of simple chemotherapy. We tried to add anlotinib to the first-line treatment with Durvalumab and Chemotherapy in patients with ES-SCLC to observe the efficacy and safety.